Cellebrite reports Q4 net income of USD 21.26 million, up 10.3%

Reuters
02/11
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> reports Q4 net income of USD 21.26 million, up 10.3%

Cellebrite reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, revenue was USD 128.82 million, with gross profit reaching USD 109.13 million and a gross margin of 84.7%. Operating income for the quarter was USD 20.81 million, reflecting an operating margin of 16.2%. Net income stood at USD 21.26 million. Cash flow from operating activities in Q4 totaled USD 86.81 million. For the full year 2025, revenue was USD 475.68 million, representing an 18% increase. Gross profit for the year was USD 400.50 million, with a gross margin of 84.2%. Operating income reached USD 66.48 million, and net income was USD 78.33 million. Cash flow from operating activities for the year amounted to USD 173.54 million. Total annual recurring revenue $(ARR)$ grew by 21% to USD 480.80 million for 2025. Non-GAAP net income for the year was USD 36.70 million, while adjusted EBITDA was USD 38.30 million, with an adjusted EBITDA margin of 29.8%. Management highlighted that Q4 2025 capped a year of meaningful strategic progress, noting strong ARR expansion, sustained subscription momentum, particularly in SaaS and cloud-enabled solutions, and robust free cash flow generation. The company stated it is well positioned entering 2026, aiming to scale efficiently and reaccelerate ARR growth, while maintaining strong operating profitability and a 30%-plus free cash flow margin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10